Login to Your Account


Potential of oncolytic viruses back on industry's radar screen

By Peter Winter

Monday, March 20, 2017

Research on the potential of oncolytic viruses to treat various cancer types has waxed and waned over the past decade as promising early results failed to translate into clinical successes. However, these cancer destroying missiles are now firmly back on the industry's radar screen following the late 2015 FDA approval of the first oncolytic virus agent, Amgen Inc.'s Imlygic (talimogene laherparepvec) for nonresectable metastatic melanoma. The therapeutic is derived from a herpes simplex virus that has been genetically engineered to infect cancer cells and to generate granulocyte macrophage colony-stimulating factor (GM-CSF).

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription